After working under an agreement in principle for two years,Affymax Research Institute and Alza Corp., both of Palo Alto,Calif., have formally established a pharmaceutical developmentprogram.
As a result, Affymax (NASDAQ:AFMXF) will apply itsproprietary chemistries to modify currently marketed drugs, ordrugs in late stages of clinical development, for use with Alza's(ASE:AZA) electrotransport technology.
Electrotransport involves using low electric currents to increaseabsorption of large molecules across the skin.
(c) 1997 American Health Consultants. All rights reserved.